My Companies
Notification
Account
Log Out
Login
USFDA inspected Mahi Drugs, material subsidiary's API facility at Jawaharlal Nehru Pharma City, Parawada, from September 15-18, 2026, concluding with zero Form 483 observations, matching the January 2025 inspection outcome.
No events have occurred recently